A phase 3, open-label, randomized, parallel-group, multi-center study to evaluate the safety and immunogenicity of Novartis meningococcal ACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants.

Trial Profile

A phase 3, open-label, randomized, parallel-group, multi-center study to evaluate the safety and immunogenicity of Novartis meningococcal ACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2014

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 16 Nov 2011 Results of the US subjects published in the Pediatric Infectious Disease Journal.
    • 29 Jul 2011 Actual end date changed from 14 Dec 2010 to Nov 2009 as reported by ClinicalTrials.gov.
    • 29 Jul 2011 Actual initiation date changed from Jul 2010 to May 2007 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top